Core Insights - Tevogen Bio Holdings Inc. expresses gratitude to the U.S. Department of Health and Human Services for addressing Long COVID through roundtables focused on patient experiences and research [1] - Approximately 20 million adults in the U.S. are affected by Long COVID, leading to significant economic consequences due to workforce absenteeism and productivity losses [2] - Tevogen's investigational drug, TVGN 489, shows promising results in clinical trials and may play a crucial role in addressing the Long COVID public health crisis [3] Company Developments - The CEO of Tevogen emphasizes the importance of addressing the lasting consequences of SARS-CoV-2, highlighting the potential of TVGN 489 to restore health for those affected by Long COVID [4] - Tevogen is committed to developing accessible and affordable personalized therapeutics through its ExacTcell™ platform, which focuses on precision T cell therapies [4]

Industry Overview - The pharmaceutical sector is projected to reach global market revenue of $1.21 trillion by 2025, driven by advancements in treatments and increasing demand for specialty drugs [1] Company Performance - AbbVie (ABBV) has a market capitalization exceeding $320 billion and has seen a year-to-date increase of over 24%, outperforming the broader pharmaceutical industry [2] - AbbVie's stock reached a record high of $221.76 following the extension of exclusivity for its top immunology drug, Rinvoq, until at least April 2037, providing an additional four years of protection from generic competition [3][4] - AbbVie has experienced a stock increase of 14.11% over the past 52 weeks and a 24.23% increase year-to-date [5] Financial Metrics - AbbVie trades at a forward price-to-earnings (P/E) ratio of 18.11x, which is close to the healthcare sector average of 18.19x, indicating comparable earnings potential [6] - The company's second-quarter net revenues were reported at $15.4 billion, reflecting a 6.6% increase from the previous year, primarily driven by the immunology segment [7] - Within the immunology segment, Skyrizi generated $4.4 billion in sales, while Rinvoq contributed $2 billion [7] - Neuroscience products grew by 24.2% to nearly $2.7 billion, with contributions from Vraylar and Botox Therapeutic, while oncology revenues increased to $1.7 billion and aesthetics saw an 8% decline to $1.3 billion [8]

Core Insights - Alkermes plc is advancing in the development of treatments for neurological and psychiatric disorders, focusing on conditions like alcohol and opioid dependence, schizophrenia, and bipolar I disorder, while also exploring narcolepsy and idiopathic hypersomnia [1] - The appointment of Joshua Reed as Chief Financial Officer is expected to enhance Alkermes' commercial performance and pipeline progression, leveraging his extensive experience in the biotechnology and pharmaceutical sectors [2] - Alkermes demonstrates a robust market position with a P/E ratio of 12.77, a price-to-sales ratio of 2.96, and an enterprise value to sales ratio of 2.66, indicating favorable market valuation [3] Financial Health - The company has a low debt-to-equity ratio of 0.045, reflecting prudent debt management, and a strong current ratio of 3.23, indicating solid short-term financial health and liquidity [4] - Analysts have set optimistic price targets for Alkermes, projecting potential price increases of 54.4% and 65.68% from the current stock price [4]

Core Insights - TimesSquare Capital Management reported a gross return of 11.28% and a net return of 11.02% for its "U.S. Small Cap Growth Strategy" in Q2 2025, underperforming the Russell 2000 Growth Index which returned 11.97% [1] - The fund highlighted Stevanato Group S.p.A. (NYSE:STVN) as a key investment, noting its significant stock performance with a one-month return of 18.79% and a 52-week gain of 39.44% [2][3] Company Performance - Stevanato Group S.p.A. closed at $26.87 per share on September 11, 2025, with a market capitalization of $7.335 billion [2] - The company experienced a 20% stock increase following a strong first quarter performance, particularly in its Biopharmaceutical and Diagnostic Solutions segment, with stabilizing vial demand and reduced destocking [3] Investment Sentiment - Despite the positive outlook for Stevanato Group S.p.A., it was not among the 30 most popular stocks among hedge funds, with only 8 hedge fund portfolios holding the stock at the end of Q2 2025, down from 10 in the previous quarter [4] - The analysis suggests that while Stevanato Group S.p.A. has potential, certain AI stocks may offer greater upside potential and lower downside risk [4]

Core Viewpoint - TimesSquare Capital Management's "U.S. Small Cap Growth Strategy" reported strong performance in Q2 2025, with a gross return of 11.28% and a net return of 11.02%, although slightly underperforming the Russell 2000 Growth Index which returned 11.97% [1] Company Summary - Insmed Incorporated (NASDAQ:INSM) is highlighted as a key stock in the portfolio, focusing on developing therapeutic products for serious and rare diseases [2][3] - Insmed's stock experienced a one-month return of 14.12% and a remarkable 97.25% increase over the past 52 weeks, closing at $145.79 per share with a market capitalization of $30.815 billion as of September 11, 2025 [2] - The company reported a significant 31% increase during the quarter, driven by positive safety and efficacy data from its Phase 2 trial of Treprostinil Palmitil inhalation powder for treating arterial hypertension [3] Investment Interest - Insmed was held by 82 hedge fund portfolios at the end of Q2 2025, an increase from 64 in the previous quarter, indicating growing interest among institutional investors [4] - Despite the potential of Insmed, some analysts suggest that certain AI stocks may offer greater upside potential and less downside risk [4]

Core Viewpoint - Scholar Rock Holding Corp. (NASDAQ:SRRK) is considered a promising multibagger stock, primarily driven by optimism surrounding its lead drug candidate, apitegromab, which has seen significant stock performance fluctuations as the company approaches a potential U.S. market launch in Q3 2025 [1] Group 1: Drug Candidate and Market Potential - Apitegromab is the first muscle-targeted therapy to show clinically meaningful and statistically significant functional improvement in spinal muscular atrophy (SMA), with a global market opportunity estimated to exceed $2 billion [2] - Analyst Amy Li from Jefferies initiated coverage with a Buy rating and a $50 price target, emphasizing the strong commercial opportunity for apitegromab, particularly if FDA approval includes patients aged two and older across SMA types 1-4 [3] - Risk-adjusted peak sales for apitegromab are modeled at $1.8 billion, with a 90% probability of success for patients over two years of age and 50% for those under two [4] Group 2: Pipeline and Future Potential - The company is also developing pipeline candidate SRK-439 for other neuromuscular conditions, including Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), as well as exploring applications in obesity through external partnerships [5]

Core Insights - Jeito Capital has made a significant investment in Odyssey Therapeutics, participating in an oversubscribed $213 million Series D financing round aimed at advancing treatments for autoimmune diseases with high unmet needs [1][2]. Company Overview - Odyssey Therapeutics, founded in 2021, is a clinical-stage biopharmaceutical company focused on transforming the standard of care for autoimmune and inflammatory diseases through targeted medicines [3][11]. - The company has developed comprehensive drug discovery and development capabilities in both the United States and Europe, achieving multiple clinical milestones in a short time frame [3][11]. Investment Details - Jeito Capital is the largest European contributor to the Series D financing, joining a group of new investors including Affinity Asset Advisors, Dimension Capital, Lightspeed Ventures, TPG Life Sciences Innovations, and Wedbush Healthcare Partners [2]. - The funds raised will be utilized to advance Odyssey's clinical and preclinical programs, particularly focusing on small-molecule therapies for complex autoimmune diseases [5][8]. Product Pipeline - Odyssey's lead compound, OD-07656, is an oral small-molecule RIPK2 scaffolding inhibitor targeting Inflammatory Bowel Disease (IBD), including ulcerative colitis and Crohn's disease, which affect millions globally [4]. - The second program involves an oral small molecule IRAK4 scaffolding inhibitor in preclinical development, aimed at treating various inflammatory diseases such as atopic dermatitis and osteoarthritis [5]. Strategic Importance - Jeito Capital's investment reflects its expertise in immunology and inflammation, building on previous successful investments in the sector, such as HI-BioTM, which was acquired by Biogen for up to $1.8 billion [6]. - The investment is expected to enhance Odyssey's capabilities in developing differentiated therapies that address significant treatment gaps in the autoimmune disease space [6][7].

Risk Disclosure - Options trading involves significant risk and is not appropriate for all investors [1] - Certain complex options strategies carry additional risk [1] Investment Ideas & Market Commentary - Tony discusses tech valuation concerns and potential interest rate cuts [1] - A trade idea for a biopharmaceutical company is shared [1] - Looks back to a recent trade for an American multinational search company [1] Resources & Engagement - Options Disclosure Document is available at provided link [1] - In the Money resources are available at provided link [1] - Weekly trade ideas are discussed on Fridays at 1:30 pm ET [1] - Sign up for more tips and insights from the team [1] - Fidelity is active on various social media platforms including YouTube, Reddit, Instagram, TikTok, Facebook, LinkedIn, Discord, and X (formerly Twitter) [1]

Company Overview - PreveCeutical Medical Inc. is a health sciences company focused on developing innovative preventive and curative therapies using organic and nature-identical products [5] - The company has five research and development programs targeting diabetes, obesity, and other health issues, including dual gene therapy and non-addictive analgesic peptides [5] Leadership Appointment - BioGene Therapeutics Inc., a wholly owned subsidiary of PreveCeutical, appointed Dr. Francis Tavares as Chief Technology Officer effective August 19, 2025 [1][4] - Dr. Tavares has extensive experience in the biopharmaceutical industry, previously serving as President, CEO, and Founder of ChemoGenics BioPharma, and has a strong background in drug discovery and medicinal chemistry [2][3] Dr. Tavares' Contributions - Dr. Tavares has a PhD in Organic Chemistry and has led the development of significant drug candidates, including Trilaciclib and Lerociclib, demonstrating a successful track record in advancing drug candidates to clinical trials [3] - His appointment is expected to enhance BioGene's capabilities in drug discovery and product commercialization, benefiting both patients and investors [4] BioGene Therapeutics Inc. Overview - BioGene is focused on advancing innovative therapies in metabolic health and gene-based treatments, with a subsidiary in Australia that leverages a 43.5% R&D tax cashback incentive [6] - The company is engaged in research aimed at addressing the global diabetes and obesity crisis through gene therapy-based approaches [6]

Core Viewpoint - Tevogen Bio Holdings Inc. reported improved operational efficiency and reduced losses in its financial results for Q2 2025, indicating a positive trajectory towards anticipated revenue by the end of 2026 [1][2][3]. Financial Performance - For the three months ended June 30, 2025, the loss from operations was $5.4 million, a decrease from $8.6 million in the same period of 2024 [2][7]. - The net loss for the quarter was $5.5 million, compared to $9.7 million in Q2 2024, reflecting a significant improvement in financial performance [2][7]. Operational Strategy - The company is focused on maximizing capital efficiency and has access to sufficient financing to support its growth plans [3][7]. - Tevogen is in the process of establishing its own GMP manufacturing facility, which is a strategic move to enhance production control and accelerate product development timelines [4][7]. Market Position and Future Outlook - Tevogen acknowledges the limited growth in the market but emphasizes that it is building infrastructure, advancing AI, and strengthening internal capabilities [3][7]. - The company is exploring options to address its current limited tradable float to better meet investor demand [3][7].